APOE4 Motif Gene Modulation via NRF1-Targeted Antisense Oligonucleotides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing, treating, and preventing Alzheimer's disease (AD) are inadequate as they do not address the underlying cause of the disease, leading to ineffective treatments with significant side effects and limited impact on disease progression.
Innovation Solution
The method involves modulating the expression of APOE4 motif-mediated genes, specifically targeting the NRF1 transcription factor to inhibit aberrant activity of FBXO46, which is believed to cause AD, using molecules such as oligonucleotides and peptides to regulate gene expression and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA approved Alzheimer's drugs are used, then symptoms are treated, but side effects are significant and disease progression is not slowed
Solution Approach 1:
The patent extracts and targets the specific harmful mechanism (APOE4 motif-mediated gene expression) from the complex disease pathology. By using antisense oligonucleotides to specifically inhibit the expression of genes mediated by the APOE4 motif, the treatment addresses the root cause rather than symptoms, thereby improving effectiveness while avoiding the broad-spectrum side effects of current drugs.
Solution Approach 2:
The patent introduces antisense oligonucleotides as intermediary molecules that mediate between the APOE4 genetic risk factor and the downstream gene expression. These oligonucleotides bind to mRNA transcripts of APOE4 motif-mediated genes, preventing their translation into harmful proteins, thus creating a targeted intervention point that avoids the side effects of direct symptomatic treatment.
2Ease of operation
If current Alzheimer's drugs are used, then some symptom relief is achieved, but the underlying pathology is not treated
Solution Approach 1:
The patent employs preliminary action by targeting gene expression at an early stage before full disease manifestation. By inhibiting APOE4 motif-mediated gene expression through antisense oligonucleotides, the treatment prevents the accumulation of harmful proteins and downstream pathological changes, thereby modifying the disease course rather than merely managing symptoms after they appear.
Solution Approach 2:
The patent converts the harmful effect of APOE4 motif-mediated gene expression into a beneficial therapeutic target. By specifically designing oligonucleotides that bind to and inhibit the expression of these genes, the treatment transforms the genetic risk factor into a precise intervention point, enabling disease modification while avoiding the harm of non-specific symptomatic treatments.
3Reliability
If APOE4 motif-mediated gene expression is inhibited, then disease progression is delayed and symptoms reversed, but treatment complexity increases
Solution Approach 1:
The patent replaces complex mechanical or chemical drug delivery systems with a more elegant molecular biology-based approach. By using antisense oligonucleotides that naturally bind to target mRNA through complementary base pairing, the treatment achieves specific gene expression inhibition without requiring complex delivery mechanisms, thereby reducing overall treatment complexity while maintaining high disease modification capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach targets the actual cause of AD, delaying onset, preventing progression, and reversing symptoms, providing disease-modifying therapies rather than merely treating symptoms.
Implementation Method 1
modulating the expression of APOE4 motif-mediated genes, specifically targeting the NRF1 transcription factor to inhibit aberrant activity of FBXO46
Data Source
AI summary
The present invention provides compositions and methods using APOE4 motif-mediated genes and expression products thereof for diagnosis, treatment and prevention of Alzheimer's disease and mild cognitive impairment. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose Alzheimer's disease or mild cognitive impairment based on APOE4 motif-mediated genes.